USANA Health Sciences (NYSE:USNA) Insider Sells $95,197.74 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider Joshua Foukas sold 4,461 shares of USANA Health Sciences stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $21.34, for a total transaction of $95,197.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

USANA Health Sciences Stock Down 1.7%

Shares of USNA stock opened at $21.29 on Thursday. The firm has a market cap of $389.09 million, a P/E ratio of 38.70, a PEG ratio of 0.90 and a beta of 0.67. The company has a 50 day moving average of $20.77 and a 200-day moving average of $23.34. USANA Health Sciences, Inc. has a 12-month low of $18.48 and a 12-month high of $38.32.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.19. The business had revenue of $226.20 million during the quarter, compared to analyst estimates of $225.96 million. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%. As a group, equities analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. National Bank of Canada FI increased its holdings in shares of USANA Health Sciences by 166.6% in the third quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock worth $53,000 after purchasing an additional 1,201 shares during the period. Tower Research Capital LLC TRC increased its stake in USANA Health Sciences by 382.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock worth $73,000 after acquiring an additional 1,901 shares during the last quarter. Parallel Advisors LLC increased its stake in USANA Health Sciences by 1,354.3% in the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock worth $76,000 after acquiring an additional 3,589 shares during the last quarter. CWM LLC raised its holdings in shares of USANA Health Sciences by 109.7% in the 2nd quarter. CWM LLC now owns 2,762 shares of the company’s stock valued at $84,000 after acquiring an additional 1,445 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of USANA Health Sciences by 52.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after acquiring an additional 1,327 shares during the last quarter. 54.25% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, December 29th. Wall Street Zen upgraded shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, Zacks Research upgraded USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, USANA Health Sciences presently has a consensus rating of “Reduce” and a consensus target price of $36.00.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.